<DOC>
	<DOCNO>NCT01481909</DOCNO>
	<brief_summary>Study title : An exploratory , randomise , double-blind , placebo control crossover study assess efficacy 20 mg Rupatadine treatment mastocytosis symptom . Study code : SMART-2010-1 Principal Investigator , Co-Investigator , sponsor , study centre ( acc . § 40 Abs . 4 AMG ) Dr. med . F. Siebenhaar , Prof. Dr. Med . M. Maurer , Allergie-Centrum-Charité , Department Dermatology Allergy , Charité - Universitätsmedizin Berlin , Charitéplatz 1 , D-10117 Berlin Biometry biostatistical analysis Division Biostatistics Clinical Epidemiology , Charité - Universitätsmedizin Berlin , Charitéplatz 1 , D-10117 Berlin Monitoring Coordination Centre Clinical Studies ( KKS ) , Charité - Universitätsmedizin Berlin , Charitéplatz 1 , D-10117 Berlin Clinical phase Phase II Primary objective : Reduction wheal flare type skin reaction standardise provocation test assess volumetric thermographic measurement . Secondary objective : Improvement additional relate symptom ( e.g . pruritus ) subjective affliction assess symptom score , DLQI , Itchy-QoL VAS . Study design : An exploratory , randomise , double-blind , placebo control crossover study Type number patient : Male female patient ( n = 30 ) cutaneous mastocytosis indolent systemic mastocytosis skin involvement Main criterion inclusion : Mastocytosis patient age 18-65 year , sign write consent , systemic corticosteroid immunosuppressive therapy , permanent severe diseases Test product , dose mode administration 20 mg Rupatadine placebo provocation testing , oral administration ( tablet ) Duration treatment : 28 day ( test do day last treatment ) Assessment efficacy : 1 . Assessment wheal flare development planimetric analysis digital photographic , volumetric , thermographic imaging ( time lapse ) treatment study medication , 2 . Additional assessment symptom , 3 . Assessment life quality Main criterion evaluation : Efficacy</brief_summary>
	<brief_title>Study Mastocytosis Rupatadine Treatment</brief_title>
	<detailed_description />
	<mesh_term>Mastocytosis</mesh_term>
	<criteria>1 . Chronic stable symptomatic maculopapulous cutaneous mastocytosis indolent systemic mastocytosis skin involvement positive Darier 's Sign 2 . Age 18 65 year . 3 . Female patient must use highly effective method birth control ( implant , injectables , combine oral contraceptive , IUDs , sexual abstinence , vasectomised partner ) , must postmenopausal , surgically sterilise , hysterectomised . 4 . Voluntarily sign write informed consent . 1 . The presence permanent severe disease , especially affect immune system , except mastocytosis 2 . History presence epilepsy , significant neurological disorder , cerebrovascular attack ischemia 3 . History presence myocardial infarction cardiac arrhythmia require drug therapy , hyper/hypokalemia , bradycardia &lt; 50bpm , QTc interval &gt; 440ms 4 . Evidence severe renal dysfunction ( creatinine &gt; 1,5 x upper reference value ) 5 . Evidence significant hepatic disease ( liver enzymes &gt; 2 x upper reference value ) 6 . History adverse reaction RUP , ingredients IMP 7 . Presence active cancer require chemotherapy radiation therapy 8 . Aggressive systemic mastocytosis 9 . History presence alcohol abuse drug addiction 10 . Participation clinical trial within 4 week prior enrolment 11 . Commitment institution term § 40 Abs . 1 S. 3 Nr . 4 AMG 12 . Intake antihistamine leukotriene antagonist within 7 day prior begin study 13 . Intake oral corticosteroid within 14 day prior begin study 14 . Use depot corticosteroid chronic systemic corticosteroid within 21 day begin study 15 . Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Assessment wheal flare development</keyword>
	<keyword>Assessment life quality</keyword>
</DOC>